Evidence mapPaperPMID 3283935Full record

ReviewScience (New York, N.Y.)1988

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

R W Mahley

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Science (New York, N.Y.), 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07738276 (Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity), which is not on this map. Cited by 1,113 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,113citing papers in PubMed, 6 pooled it
88.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07738276 phase3not yet recruitingstarted 2026, after this paper: background citation

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial

Ran2026Enrolled60Registered outcomes27Posted comparisons0ConditionsHeart Failure and Reduced Ejection Fraction, Obesity & Overweight, TirzepatideArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

1,113 citing papers in PubMed, 6 syntheses or guidelines pooled it, 4,016 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Apolipoprotein EDisease markers · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Transcriptome Sequencing and Identification ofAnimals : an open access journal from MDPI · 2026
    Article
  19. Article
  20. Atractylenolide I mitigates Alzheimer's disease pathology in ApoEActa biochimica et biophysica Sinica · 2026
    Article

1,053 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

R W MahleyGladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608.
Gladstone Institutes · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein E is a plasma protein that serves as a ligand for low density lipoprotein receptors and, through its interaction with these receptors, participates in the transport of cholesterol and other lipids among various cells of the body. A mutant form of apolipoprotein E that is defective in binding to low density lipoprotein receptors is associated with familial type III hyperlipoproteinemia, a genetic disorder characterized by elevated plasma cholesterol levels and accelerated coronary artery disease. Apolipoprotein E is synthesized in various organs, including liver, brain, spleen, and kidney, and is present in high concentrations in interstitial fluid, where it appears to participate in cholesterol redistribution from cells with excess cholesterol to those requiring cholesterol. Apolipo-protein E also appears to be involved in the repair response to tissue injury; for example, markedly increased amounts of apolipoprotein E are found at sites of peripheral nerve injury and regeneration. Other functions of apolipoprotein E, unrelated to lipid transport, are becoming known, including immunoregulation and modulation of cell growth and differentiation.

Indexed as

Amino Acid SequenceApolipoproteins EBiological TransportCholesterolGene Expression RegulationHumansHyperlipoproteinemia Type IIIImmunityLipid MetabolismMolecular Sequence DataPolymorphism, GeneticProtein ConformationReceptors, LDLApolipoproteins ECholesterolReceptors, LDL

Identifiers

PMID3283935
OpenAlexW2034968148

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.